Logo for University of Iowa Health Care This logo represents the University of Iowa Health Care

Lentivirus Shuttle Plasmids

LentivirusThe University of Iowa Viral Vector Core provides shuttle plasmids at no cost when intended for virus production. (A $50 FedEx overnight shipping fee will apply if no FedEx account is provided). Material sent includes 10μl of plasmid. We suggest that you digest the plasmid after any amplification step.

Interested in Ordering?

Please view our ordering information for shuttle plasmids to learn how to register for an account, place orders for shuttle plasmids and make payment through our online system.

Plasmid Backbone

The pFIV3.2 backbone is based on the pVETL Backbone developed by Novartis/Chiron Technologies and modified by Patrick L. Sinn, PhD (University of Iowa) to improve safety and transgene expression:

  • The lentiviral central polypurine tract and the central termination sequence were added directly downstream of the gag sequence.
  • The Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element, WPRE, was added directly upstream of the rev response element, RRE.
  • The major splice donor and the initial gag sequence each have a mutation but the packaging signal was retained.
  • The FIV 3’LTR was rendered “self-inactivating” by deleting a portion of the U3 region.

 

G0654 pFIV3.2mcs

Cat: G0654

pFIV3.2 backbone, multiple cloning site.


G0655 pFIV3.2CMVmcs

Cat: G0655

pFIV3.2 backbone, CMV (Cytomegalovirus) Promoter, multiple cloning site.


G0656 pFIV3.2RSVmcs

Cat: G0656

pFIV3.2 backbone, RSV (Rous sarcoma virus) Promoter, multiple cloning site.


G0667 pFIV3.2CAGmcs

Cat: G0667

pFIV3.2 backbone, CAG (CMV enhancer fused to the chicken beta-actin promoter) Promoter, multiple cloning site.


G0356 pFIV3.2TREmcs

Cat: G0356

pFIV3.2 backbone, TRE tight (TET Response Element) Promoter, multiple cloning site.


G0668 pFIV3.2EF1amcs

Cat: G0668

pFIV3.2 backbone, Human elongation factor-1 alpha (EF1a) Promoter, multiple cloning site..


G0863 pFIV3.2PGKmcs

Cat: G0863

pFIV3.2 backbone, PGK(Phosphoglycerate kinase) Promoter, multiple cloning site.


G0752 pFIV3.2mcswtIRESeGFP

Cat: G0752

pFIV3.2 backbone, multiple cloning site, wild type IRES (internal ribosome entry site), eGFP (enhanced green fluorescent protein. The IRES-eGFP functions as a non-fusion protein reporter without the addition of a second promoter.


G0754 pFIV3.2CMVmcswtIRESeGFP

Cat: G0754

pFIV3.2 backbone, multiple cloning site, wild type IRES (internal ribosome entry site), eGFP (enhanced green fluorescent protein). The IRES-eGFP functions as a non-fusion protein reporter without the addition of a second promoter.


G0411 pFIV3.2mcseGFP

Cat: G0411

pFIV3.2 backbone, multiple cloning site, eGFP (enhanced green fluorescent protein).


G0859 pFIV3.2CMVmcwtIRESZeocin

Cat: G0859

pFIV3.2 backbone, CMV (Cytomegalovirus) Promoter, multiple cloning site, wild type IRES (internal ribosome entry site), Zeocin as a selectable marker.


G0913 pFIV3.2CMVmcwtIRESNeomycin

Cat: G0913

pFIV3.2 backbone, CMV (Cytomegalovirus) Promoter, multiple cloning site, wild type IRES (internal ribosome entry site), Neomycin as a selectable marker.


G0776 pFIV3.2CAGmcswtIRESeGFP

Cat: G0776

pFIV3.2 backbone, CAG (CMV enhancer fused to the chicken beta-actin promoter) Promoter, multiple cloning site, wild type IRES (internal ribosome entry site), eGFP.


G0860 pFIV3.2mcswtIRESZeocin

Cat: G0860

pFIV3.2 backbone, multiple cloning site, wild type IRES (internal ribosome entry site), Zeocin as a selectable marker.


G0432 pFIV3.2mcsCMVeGFP

Cat: G0432

pFIV3.2 backbone backbone, multiple cloning site, CMV (Cytomegalovirus) Promoter, eGFP (enhanced green fluorescent protein). Suitable for RNAi cassettes.


G0973 pFIV3.2mU6shSafeCMVeGFP

Cat: G0973

pFIV3.2 backbone backbone, Mouse U6 Promoter driving a scrambled shRNA control shSafe cassette, CMV (Cytomegalovirus) Promoter, eGFP (enhanced green fluorescent protein).

Please reference: Boudreau, R. L., et al. (2011). "Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's Disease." Mol Ther 19(12): 2169-2177.